Celiac plexus block plus first-line systemic therapy for advanced biliopancreatic cancer with pain
Official title: A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade in Patients With Advanced Biliopancreatic Malignancies and Cancer-Related Pain
Run by Tongji Hospital · NCT07326137 · Data updated 2026-11-12
This study will try giving a celiac plexus block alongside standard first-line cancer drugs to see if it reduces pain and helps people with advanced bile duct or pancreatic cancer.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 103 (estimated) |
| Sponsor | Tongji Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Wuhan, Hubei) |
| Status | Recruiting |
| Started | December 26, 2025 |
| Main results expected | June 26, 2028 |
| Study ends | December 26, 2028 |
| Registry record updated | February 11, 2026 |
| Trial ID | NCT07326137 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with histologically confirmed inoperable advanced biliary tract or pancreatic cancer who have cancer-related abdominal pain (NRS ≥4 for >1 week), are planned for first-line systemic therapy, have ECOG 0–2 and an expected survival of at least 3 months, and have no prior CPN.
✕Probably not a fit
Patients with contraindications to CPN, prior celiac plexus neurolysis, severe cardiac/hepatic/renal impairment, coagulation disorders, or very limited life expectancy are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-center observational cohort of adults with inoperable advanced biliary tract or pancreatic cancer who have moderate to severe abdominal pain and are scheduled for first-line systemic therapy. Participants who undergo celiac plexus neurolysis (CPN) will be followed alongside a contemporary control cohort receiving systemic therapy alone, with treatment choices made by the treating physicians per routine practice. Co-primary endpoints are pain response (≥2-point drop on the Numeric Rating Scale or ≥50% opioid reduction sustained 4 weeks) and objective tumor response by RECIST 1.1, and secondary endpoints include progression-free survival, overall survival, quality of life, and safety. Patients will be followed for up to two years to capture pain control, oncologic outcomes, and adverse events.
Why it matters
Potential benefit: If successful, combining CPN with first-line systemic therapy could provide better pain relief, reduce opioid needs, and improve quality of life while allowing standard cancer treatment to continue.
How similar studies have gone: Celiac plexus neurolysis has been shown in prior studies to reduce pain in pancreatic cancer, but prospectively combining CPN with first-line systemic therapy for biliopancreatic cancers in a comparative cohort is relatively untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed advanced biliopancreatic malignancy (including biliary tract cancer or pancreatic cancer). * Cancer-related pain: Baseline Numeric Rating Scale (NRS) pain score ≥ 4 points for over 1 week, with plans to receive celiac plexus neurolysis (CPN). * Scheduled to receive a first-line systemic treatment regimen (e.g., PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy/targeted therapy). * ECOG Performance Status of 0-2 and an estimated life expectancy of ≥ 3 months. Exclusion Criteria: * Previous history of celiac plexus neurolysis or ablation. * Coagulation disorders (INR \> 1.5, platelet count \< 50 × 10⁹/L). * Severe cardiac, hepatic, or renal insufficiency (Child-Pugh Class C, estimated glomerular filtration rate (eGFR) \< 30 mL/min, NYHA Class III-IV heart failure). * Contraindications to celiac plexus block (e.g., local infection, anatomical variation). * Any other condition that, in the investigator's judgment, would preclude safe participation in the study.
Where it's running
-
Tongji Hospital
Wuhan, Hubei, China Recruiting
Study contacts
- Study coordinator: Yang Dr. Wu, M.D.
- Email: 255001907@qq.com
- Phone: 13636076910
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Building a short video and audio database of cancer pain to help AI recognize patient pain
This project collects short face and voice recordings from adults with cancer who do and don't have pain to help test AI that tries to recognize pain from expressions.
-
IBI343 plus gemcitabine and albumin‑bound paclitaxel for advanced pancreatic cancer
This trial will test whether adding IBI343 to gemcitabine and albumin‑bound paclitaxel helps people with CLDN18.2‑positive advanced pancreatic adenocarcinoma.
-
Treatment of advanced pancreatic cancer using CHT102
This study is testing a new CAR-T cell therapy called CHT102 to see if it can safely help people with advanced pancreatic cancer.
-
Using tumor infiltrating lymphocytes to treat advanced liver and pancreatic cancers
This study is testing a new treatment using immune cells from tumors to see if it can help people with advanced liver and pancreatic cancers who haven't responded to regular therapies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.